JP2003530837A - タイプＩＩ性腺刺激ホルモン放出ホルモンレセプター（タイプＩＩＧｎＲＨ−Ｒ）及びそれをコードするポリヌクレオチド - Google Patents
タイプＩＩ性腺刺激ホルモン放出ホルモンレセプター（タイプＩＩＧｎＲＨ−Ｒ）及びそれをコードするポリヌクレオチドInfo
- Publication number
- JP2003530837A JP2003530837A JP2001576095A JP2001576095A JP2003530837A JP 2003530837 A JP2003530837 A JP 2003530837A JP 2001576095 A JP2001576095 A JP 2001576095A JP 2001576095 A JP2001576095 A JP 2001576095A JP 2003530837 A JP2003530837 A JP 2003530837A
- Authority
- JP
- Japan
- Prior art keywords
- type
- gnrh
- receptor
- peptide
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010021290 LHRH Receptors Proteins 0.000 title claims abstract description 58
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 27
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 27
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 27
- 102000008238 LHRH Receptors Human genes 0.000 title claims abstract description 7
- 102100033851 Gonadotropin-releasing hormone receptor Human genes 0.000 title claims description 124
- 101710082444 Gonadotropin-releasing hormone receptor Proteins 0.000 title claims description 73
- 241000282414 Homo sapiens Species 0.000 claims abstract description 58
- 241001515942 marmosets Species 0.000 claims abstract description 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 13
- 102000005962 receptors Human genes 0.000 claims description 107
- 108020003175 receptors Proteins 0.000 claims description 107
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 230000027455 binding Effects 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 230000019491 signal transduction Effects 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 3
- 239000003433 contraceptive agent Substances 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 6
- 230000002254 contraceptive effect Effects 0.000 claims 2
- 101800001693 R-peptide Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 55
- JNVXACSECVMTSD-XJIZABAQSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(1h-imidazol-5-yl)-1-oxopropa Chemical compound NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 JNVXACSECVMTSD-XJIZABAQSA-N 0.000 description 41
- 108700015863 His(5)-Trp(7)-Tyr(8)- LHRH Proteins 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 41
- 101710118786 Gonadotropin-releasing hormone II receptor Proteins 0.000 description 28
- 102100033845 Putative gonadotropin-releasing hormone II receptor Human genes 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 26
- 102000009151 Luteinizing Hormone Human genes 0.000 description 24
- 108010073521 Luteinizing Hormone Proteins 0.000 description 24
- 229940040129 luteinizing hormone Drugs 0.000 description 24
- 102000006771 Gonadotropins Human genes 0.000 description 20
- 108010086677 Gonadotropins Proteins 0.000 description 20
- 239000002622 gonadotropin Substances 0.000 description 20
- 230000028327 secretion Effects 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 16
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 15
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 229940028334 follicle stimulating hormone Drugs 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- 102000004389 Ribonucleoproteins Human genes 0.000 description 10
- 108010081734 Ribonucleoproteins Proteins 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 108091060211 Expressed sequence tag Proteins 0.000 description 9
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 9
- 241001494479 Pecora Species 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000001817 pituitary effect Effects 0.000 description 9
- 230000003248 secreting effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 206010062767 Hypophysitis Diseases 0.000 description 8
- 102000043136 MAP kinase family Human genes 0.000 description 8
- 108091054455 MAP kinase family Proteins 0.000 description 8
- 210000003635 pituitary gland Anatomy 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000001850 reproductive effect Effects 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 7
- 210000003016 hypothalamus Anatomy 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 6
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 6
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 229940094892 gonadotropins Drugs 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 5
- 241000282560 Macaca mulatta Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 210000002637 putamen Anatomy 0.000 description 5
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 5
- 229940055619 selenocysteine Drugs 0.000 description 5
- 235000016491 selenocysteine Nutrition 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108010059616 Activins Proteins 0.000 description 4
- 102000005606 Activins Human genes 0.000 description 4
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 210000004727 amygdala Anatomy 0.000 description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 210000003814 preoptic area Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- NMJREATYWWNIKX-XJIZABAQSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 NMJREATYWWNIKX-XJIZABAQSA-N 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000270934 Rana catesbeiana Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108091023045 Untranslated Region Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 210000004198 anterior pituitary gland Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000008045 co-localization Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 210000000877 corpus callosum Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 210000001652 frontal lobe Anatomy 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- 230000003227 neuromodulating effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000010539 reproductive behavior Effects 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 210000000331 sympathetic ganglia Anatomy 0.000 description 3
- 210000003478 temporal lobe Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000938605 Crocodylia Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000996727 Homo sapiens Gonadotropin-releasing hormone receptor Proteins 0.000 description 2
- 101000668140 Homo sapiens RNA-binding protein 8A Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102100039691 RNA-binding protein 8A Human genes 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001767 medulla oblongata Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 210000004281 subthalamic nucleus Anatomy 0.000 description 2
- 210000004377 supraoptic nucleus Anatomy 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100031149 Deoxyribonuclease gamma Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 101800000477 Gonadoliberin-1 Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 244000028344 Primula vulgaris Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006543 gametophyte development Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010035313 glycerophosphoinositol glycerophosphodiesterase Proteins 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 239000012073 inactive phase Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- -1 inositol phosphates Chemical class 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001073 mediodorsal thalamic nucleus Anatomy 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 210000002975 pon Anatomy 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000026234 pro-estrus Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0009269A GB0009269D0 (en) | 2000-04-15 | 2000-04-15 | Receptor |
| GB0009269.2 | 2000-04-15 | ||
| GB0014761.2 | 2000-06-17 | ||
| GB0014761A GB0014761D0 (en) | 2000-06-17 | 2000-06-17 | Receptor |
| US21523200P | 2000-06-30 | 2000-06-30 | |
| US60/215,232 | 2000-06-30 | ||
| PCT/GB2001/001755 WO2001078796A1 (fr) | 2000-04-15 | 2001-04-17 | Recepteur de la gonadoliberine de type ii et polynucleotides codant pour ce recepteur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003530837A true JP2003530837A (ja) | 2003-10-21 |
Family
ID=27255670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001576095A Pending JP2003530837A (ja) | 2000-04-15 | 2001-04-17 | タイプＩＩ性腺刺激ホルモン放出ホルモンレセプター（タイプＩＩＧｎＲＨ−Ｒ）及びそれをコードするポリヌクレオチド |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1337282A2 (fr) |
| JP (1) | JP2003530837A (fr) |
| KR (1) | KR20020097218A (fr) |
| AU (1) | AU2001248599A1 (fr) |
| BR (1) | BR0110098A (fr) |
| CA (1) | CA2404127A1 (fr) |
| HU (1) | HUP0301666A2 (fr) |
| IL (1) | IL152011A0 (fr) |
| NO (1) | NO20024937L (fr) |
| PL (1) | PL357684A1 (fr) |
| WO (1) | WO2001078796A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000701A2 (fr) * | 2000-06-26 | 2002-01-03 | Bayer Aktiengesellschaft | Regulation du recepteur humain couple a la proteine g semblable au recepteur de l'hormone liberant la gonadotropine |
| WO2002070701A2 (fr) * | 2001-03-01 | 2002-09-12 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Nouveau recepteur gnrh humain |
| US20050282745A1 (en) * | 2001-08-28 | 2005-12-22 | Siler-Khodr Theresa M | Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy |
| US7361633B2 (en) | 2002-07-22 | 2008-04-22 | Ardana Bioscience Limited | Screening method and anti-tumor drug candidate obtained therefrom |
| WO2004010145A2 (fr) * | 2002-07-22 | 2004-01-29 | Ardana Bioscience Limited | Procede de criblage |
| AU2003269087A1 (en) * | 2002-07-22 | 2004-02-09 | Ardana Bioscience Limited | Gnrh modulator |
| KR101038183B1 (ko) * | 2010-12-27 | 2011-06-01 | 강범준 | 조립식 파형블록과 이를 이용한 호안 경사면 피복방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2138999C (fr) * | 1992-06-23 | 2010-02-23 | Stuart C. Sealfon | Clonage et expression d'un recepteur de la gnrh |
| AU3388597A (en) * | 1996-06-13 | 1998-01-07 | University Of Cape Town | Human type ii gonadotropin-releasing hormone receptor |
-
2001
- 2001-04-17 JP JP2001576095A patent/JP2003530837A/ja active Pending
- 2001-04-17 WO PCT/GB2001/001755 patent/WO2001078796A1/fr not_active Application Discontinuation
- 2001-04-17 AU AU2001248599A patent/AU2001248599A1/en not_active Abandoned
- 2001-04-17 PL PL01357684A patent/PL357684A1/xx unknown
- 2001-04-17 BR BR0110098-0A patent/BR0110098A/pt not_active Application Discontinuation
- 2001-04-17 KR KR1020027013776A patent/KR20020097218A/ko not_active Application Discontinuation
- 2001-04-17 HU HU0301666A patent/HUP0301666A2/hu unknown
- 2001-04-17 IL IL15201101A patent/IL152011A0/xx unknown
- 2001-04-17 CA CA002404127A patent/CA2404127A1/fr not_active Abandoned
- 2001-04-17 EP EP01921629A patent/EP1337282A2/fr not_active Withdrawn
-
2002
- 2002-10-14 NO NO20024937A patent/NO20024937L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20024937D0 (no) | 2002-10-14 |
| HUP0301666A2 (hu) | 2003-08-28 |
| EP1337282A2 (fr) | 2003-08-27 |
| IL152011A0 (en) | 2003-04-10 |
| CA2404127A1 (fr) | 2001-10-25 |
| WO2001078796A9 (fr) | 2002-02-28 |
| AU2001248599A1 (en) | 2001-10-30 |
| BR0110098A (pt) | 2003-01-14 |
| NO20024937L (no) | 2002-12-09 |
| PL357684A1 (en) | 2004-07-26 |
| WO2001078796A3 (fr) | 2003-04-24 |
| WO2001078796A1 (fr) | 2001-10-25 |
| KR20020097218A (ko) | 2002-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Millar et al. | A novel mammalian receptor for the evolutionarily conserved type II GnRH | |
| US5545549A (en) | DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof | |
| JP4216326B2 (ja) | ヒト神経ペプチドｙ／ペプチドｙｙ／膵臓ポリペプチド受容体（ｙ４）をコードしたｄｎａ、及び該ｄｎａの使用 | |
| JP2003516746A (ja) | インヒビン・レセプタとしてのベータグリカン及びその利用法 | |
| JP2002500008A (ja) | 哺乳動物ｅｄｇ−５受容体相同体 | |
| EP0769024B1 (fr) | Yrecepteurs de la melatonine de haute affinite et leurs utilisations | |
| JP2003530837A (ja) | タイプＩＩ性腺刺激ホルモン放出ホルモンレセプター（タイプＩＩＧｎＲＨ−Ｒ）及びそれをコードするポリヌクレオチド | |
| DE69825629T2 (de) | Säugertier edg-7 rezeptor homologen | |
| Bidaud et al. | Characterization and functional expression of cDNAs encoding thyrotropin‐releasing hormone receptor from Xenopus laevis: Identification of a novel subtype of thyrotropin‐releasing hormone receptor | |
| US6965013B2 (en) | Intermedin and its uses | |
| US6500927B2 (en) | Identification and characterization of multiple splice variants of the mu-opioid receptor gene | |
| US6399315B1 (en) | Screening assays using cloned CRF receptors | |
| US6482608B1 (en) | Cloning and recombinant production of CRF receptor(S) | |
| US20030124585A1 (en) | Type II gonadotropin-releasing hormone receptor and polynucleotides encoding therefor | |
| JP2003527302A (ja) | 新規な神経ペプチドレセプターｈｆｇａｎ７２のリガンドおよびそのアゴニストまたはアンタゴニストを用いる治療方法 | |
| JP2003531599A (ja) | 食欲制御物質としてのｇｐｒ５６受容体のアゴニスト／アンタゴニスト | |
| US20020123138A1 (en) | Human VNO receptor (R1) | |
| US7081349B1 (en) | High-affinity melatonin receptor and uses thereof | |
| JP2006525782A (ja) | ヒト下垂体成長ホルモンのスプライスバリアント | |
| JP2003531638A (ja) | 食欲制御物質の同定のためのｇタンパク質共役型受容体ｇｐｒ３の使用 | |
| US20050250720A1 (en) | Novel compound | |
| You | Isolation and characterization of alternatively spliced avian vasoactive intestinal peptide, follicle-stimulating hormone-and luteinizing hormone-receptor cDNAS | |
| JP2001190276A (ja) | 新規ポリペプチドおよびそのｄｎａ | |
| JP2006526385A (ja) | 絨毛性体乳腺発育ホルモンのスプライシング変種 | |
| AU4466196A (en) | Cloning and recombinant production of crf receptor(s) |